[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review

D. J.P. van Uden; M. W. Prins; S. Siesling; J. H.W. de Wilt; C. F.J.M. Blanken-Peeters

doi:10.1016/j.critrevonc.2020.102943

[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review

D. J.P. van Uden^*, M. W. Prins, S. Siesling, J. H.W. de Wilt, C. F.J.M. Blanken-Peeters

^*Corresponding author for this work

Health Technology & Services Research

Research output: Contribution to journal › Review article › Academic › peer-review

13 Citations (Scopus)

18 Downloads (Pure)

Abstract

Up to 78 % of patients with inflammatory breast cancer (IBC) present with axillary lymph node involvement and up to 40 % with distant metastases. Previous studies indicate that 2-deoxy-2-(¹⁸F)fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography/computed tomography (PET/CT) might be used for initial staging in patients with inflammatory breast cancer (IBC). In other cancer types, [¹⁸F]FDG PET/CT has been demonstrated to be a sensitive technique, providing complementary information on locoregional and distant disease to conventional imaging modalities. This systematic review showed that ¹⁸F]FDG PET/CT detects additional locoregional lymph node metastases and distant metastases in 10.3 % of patients, that were not detected with standard staging imaging. Compared with conventional imaging procedures, [¹⁸F]FDG PET/CT had better diagnostic performance for detection of locoregional and distant metastases and should standardly be used in the diagnostic work-up of IBC patients.

Original language	English
Article number	102943
Journal	Critical Reviews in Oncology/Hematology
Volume	151
DOIs	https://doi.org/10.1016/j.critrevonc.2020.102943
Publication status	Published - 1 Jul 2020

Keywords

Positron emission tomography
Staging
Inflammatory breast cancer
22/2 OA procedure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2020.102943Licence: Taverne

Cite this

@article{bdc32acecc844e809cf92a674f2e8b9e,

title = "[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review",

abstract = "Up to 78 % of patients with inflammatory breast cancer (IBC) present with axillary lymph node involvement and up to 40 % with distant metastases. Previous studies indicate that 2-deoxy-2-(18F)fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) might be used for initial staging in patients with inflammatory breast cancer (IBC). In other cancer types, [18F]FDG PET/CT has been demonstrated to be a sensitive technique, providing complementary information on locoregional and distant disease to conventional imaging modalities. This systematic review showed that 18F]FDG PET/CT detects additional locoregional lymph node metastases and distant metastases in 10.3 % of patients, that were not detected with standard staging imaging. Compared with conventional imaging procedures, [18F]FDG PET/CT had better diagnostic performance for detection of locoregional and distant metastases and should standardly be used in the diagnostic work-up of IBC patients.",

keywords = "Positron emission tomography, Staging, Inflammatory breast cancer, 22/2 OA procedure",

author = "{van Uden}, {D. J.P.} and Prins, {M. W.} and S. Siesling and {de Wilt}, {J. H.W.} and Blanken-Peeters, {C. F.J.M.}",

note = "Elsevier deal",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.critrevonc.2020.102943",

language = "English",

volume = "151",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - [18F]FDG PET/CT in the staging of inflammatory breast cancer

T2 - A systematic review

AU - van Uden, D. J.P.

AU - Prins, M. W.

AU - Siesling, S.

AU - de Wilt, J. H.W.

AU - Blanken-Peeters, C. F.J.M.

N1 - Elsevier deal

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Up to 78 % of patients with inflammatory breast cancer (IBC) present with axillary lymph node involvement and up to 40 % with distant metastases. Previous studies indicate that 2-deoxy-2-(18F)fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) might be used for initial staging in patients with inflammatory breast cancer (IBC). In other cancer types, [18F]FDG PET/CT has been demonstrated to be a sensitive technique, providing complementary information on locoregional and distant disease to conventional imaging modalities. This systematic review showed that 18F]FDG PET/CT detects additional locoregional lymph node metastases and distant metastases in 10.3 % of patients, that were not detected with standard staging imaging. Compared with conventional imaging procedures, [18F]FDG PET/CT had better diagnostic performance for detection of locoregional and distant metastases and should standardly be used in the diagnostic work-up of IBC patients.

AB - Up to 78 % of patients with inflammatory breast cancer (IBC) present with axillary lymph node involvement and up to 40 % with distant metastases. Previous studies indicate that 2-deoxy-2-(18F)fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) might be used for initial staging in patients with inflammatory breast cancer (IBC). In other cancer types, [18F]FDG PET/CT has been demonstrated to be a sensitive technique, providing complementary information on locoregional and distant disease to conventional imaging modalities. This systematic review showed that 18F]FDG PET/CT detects additional locoregional lymph node metastases and distant metastases in 10.3 % of patients, that were not detected with standard staging imaging. Compared with conventional imaging procedures, [18F]FDG PET/CT had better diagnostic performance for detection of locoregional and distant metastases and should standardly be used in the diagnostic work-up of IBC patients.

KW - Positron emission tomography

KW - Staging

KW - Inflammatory breast cancer

KW - 22/2 OA procedure

UR - http://www.scopus.com/inward/record.url?scp=85084491244&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2020.102943

DO - 10.1016/j.critrevonc.2020.102943

M3 - Review article

C2 - 32416347

AN - SCOPUS:85084491244

SN - 1040-8428

VL - 151

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 102943

ER -

[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this